2. Academic Validation
  3. Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-alpha]imidazol-2-one derivatives

Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-alpha]imidazol-2-one derivatives

  • J Med Chem. 2004 Oct 21;47(22):5356-66. doi: 10.1021/jm049657b.
Jiang-Ping Wu 1,  Jonathan Emeigh,  Donghong A Gao,  Daniel R Goldberg,  Daniel Kuzmich,  Clara Miao,  Ian Potocki,  Kevin C Qian,  Ronald J Sorcek,  Deborah D Jeanfavre,  Kei Kishimoto,  Elizabeth A Mainolfi,  Gerald Nabozny Jr,  Charline Peng,  Patricia Reilly,  Robert Rothlein,  Rosemarie H Sellati,  Joseph R Woska Jr,  Shirlynn Chen,  Jocelyn A Gunn,  Drane O'Brien,  Stephen H Norris,  Terence A Kelly
Affiliations

Affiliation

  • 1 Research and Development, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, Connecticut 06877, USA. [email protected]
PMID: 15481974 DOI: 10.1021/jm049657b
Abstract

A novel class of lymphocyte function-associated antigen-1 (LFA-1) inhibitors is described. Discovered during the process to improve the physicochemical and metabolic properties of BIRT377 (1, Figure 1), a previously reported hydantoin-based LFA-1 inhibitor, these compounds are characterized by an imidazole-based 5,5-bicyclic scaffold, the 1,3,3-trisubstituted 1H-imidazo[1,2-alpha]imidazol-2-one (i.e. structure 3). The structure-activity relationship (SAR) shows that electron-withdrawing groups at C5 on the imidazole ring benefit potency and that oxygen-containing functional groups attached to a C5-sulfonyl or sulfonamide group further improve potency. This latter gain in potency is attributed to the interaction(s) of the functionalized sulfonyl/sulfonamide groups with the protein, likely polar-polar in nature, as suggested by SAR data. X-ray studies revealed that these bicyclic inhibitors bind to the I-domain of LFA-1 in a pattern similar to that of compound 1.

Figures